Skip to main content

Table 4 Individual endpoint risk by ADRB1 and ADRB3 genotype

From: Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome Evaluation

  Death Myocardial Infarction Heart Failure Stroke
  No. Events (%) Adjusted HR (95%CI)* n = 628 No. Events (%) Adjusted HR (95%CI)* n = 628 No. Events (%) Adjusted HR (95%CI)* n = 628 No. Events (%) Adjusted HR (95%CI)* n = 628
All Patients (n = 628)         
ADRB1 Arg389Gly         
Arg/Arg 22 (7.3) 1.00 (reference) 4 (1.3) 1.00 (reference) 11 (3.6) 1.00 (reference) 14 (4.6) 1.00 (reference)
Arg/Gly 29 (10.8) 1.27 (0.73–2.23) 13 (4.8) 3.35 (1.08–10.3) 16 (6.0) 1.28 (0.58–2.80) 9 (3.4) 0.61 (0.26–1.41)
Gly/Gly 7 (13.0) 1.65 (0.68–3.99) 3 (5.6) 3.89 (0.84–18.1) 4 (7.4) 2.12 (0.65–6.91) 4 (7.4) 1.53 (0.49–4.77)
ADRB3 Trp64Arg         
Trp/Trp 50 (9.6) 1.00 (reference) 16 (3.1) 1.00 (reference) 24 (4.6) 1.00 (reference) 21 (4.0) 1.00 (reference)
Trp/Arg + Arg/Arg 10 (9.7) 1.01 (0.50–2.04) 4 (3.9) 1.47 (0.48–4.52) 6 (5.8) 1.46 (0.58–3.67) 5 (4.8) 1.20 (0.45–3.24)
Non-obstructive CAD (n = 400)         
ADRB1         
Arg389Gly         
Arg/Arg 8 (4.1) 1.00 (reference) 0 1.00 (reference) 3 (1.5) 1.00 (reference) 5 (2.6) 1.00 (reference)
Arg/Gly 8 (4.8) 0.77 (0.29–2.05) 8 (4.8) ... 11 (6.6) 4.37 (1.12–17.0) 6 (3.6) 1.06 (0.31–3.66)
Gly/Gly 4 (11.1) 2.08 (0.60–7.18) 2 (5.6) ... 0 ... 2 (5.6) 1.54 (0.29–8.31)
ADRB3         
Trp64Arg         
Trp/Trp 17 (4.9) 1.00 (reference) 7 (2.1) 1.00 (reference) 11 (3.2) 1.00 (reference) 10 (2.9) 1.00 (reference)
Trp/Arg + Arg/Arg 4 (6.9) 1.91 (0.61–5.97) 3 (5.2) 2.94 (0.69–12.5) 3 (5.2) 2.10 (0.55–8.10) 3 (5.2) 2.35 (0.60–9.29)
  1. Abbreviations: HR, hazard ratio; 95%CI, 95% confidence interval
  2. * adjusted for age, race, presence of obstructive CAD, history of diabetes, ever-smoking, baseline systolic BP, BMI
  3. analyzed using dominant model based on minor allele frequency ≤ 0.1